Related Experiment Video
Updated: Jan 22, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer
Jing Tang1,2,3, Prson Gautam1, Abhishekh Gupta1,4
11Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Abstract:
Cancer cells with heterogeneous mutation landscapes and extensive functional redundancy easily develop resistance to monotherapies by emerging activation of compensating or bypassing pathways. To achieve more effective and sustained clinical responses, synergistic interactions of multiple druggable targets that inhibit redundant cancer survival pathways are often required. Here, we report a systematic polypharmacology strategy to predict, test, and understand the selective drug combinations for MDA-MB-231 triple-negative breast cancer cells. We started by applying our network pharmacology model to predict synergistic drug combinations. Next, by utilizing kinome-wide drug-target profiles and gene expression data, we pinpointed a synergistic target interaction between Aurora B and ZAK kinase inhibition that led to enhanced growth inhibition and cytotoxicity, as validated by combinatorial siRNA, CRISPR/Cas9, and drug combination experiments. The mechanism of such a context-specific target interaction was elucidated using a dynamic simulation of MDA-MB-231 signaling network, suggesting a cross-talk between p53 and p38 pathways. Our results demonstrate the potential of polypharmacological modeling to systematically interrogate target interactions that may lead to clinically actionable and personalized treatment options.
Insights
This study introduces a polypharmacology approach to identify effective drug combinations for triple-negative breast cancer. Combining Aurora B and ZAK kinase inhibitors shows promise for enhanced cancer cell growth inhibition.
Area of Science:
- Oncology
- Pharmacology
- Systems Biology
Background:
- Cancer cells develop drug resistance through redundant pathways, necessitating combination therapies.
- Targeting multiple pathways simultaneously can overcome resistance and improve clinical outcomes.
Purpose of the Study:
- To develop and validate a polypharmacology strategy for predicting synergistic drug combinations in MDA-MB-231 triple-negative breast cancer cells.
- To identify specific kinase targets whose combined inhibition leads to enhanced anti-cancer effects.
Main Methods:
- Network pharmacology modeling was used to predict synergistic drug combinations.
- Kinome-wide drug-target profiles and gene expression data guided target identification.
- Combinatorial siRNA, CRISPR/Cas9, and drug experiments validated synergistic interactions.
- Dynamic simulation of signaling networks elucidated the underlying mechanisms.
Main Results:
- A synergistic interaction between Aurora B and ZAK kinase inhibition was identified.
- Combined inhibition resulted in enhanced growth inhibition and cytotoxicity of cancer cells.
- A cross-talk between p53 and p38 pathways was implicated in the observed synergy.
Conclusions:
- Polypharmacological modeling can systematically identify effective drug combinations for cancer treatment.
- Targeting Aurora B and ZAK kinases offers a potential therapeutic strategy for triple-negative breast cancer.
- This approach may lead to clinically actionable and personalized cancer treatment options.
Related Concept Videos
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
Negative Regulator Molecules
Positive, Negative, and Zero Work
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...

